BCL2 and epilepsy: Preclinical studies have shown that pathways such as the Bcl-2, IL-1β, NT-3 and the MAPK pathway that are also involved in miRNA dysregulation may also be promising new horizons for diagnosis and treatment of experimental as well as clinical epilepsy.